Xiuning Le: BAY88 in pre-treated HER2-mut NSCLC

Xiuning Le shared  a post by Biagio Ricciuti, on X, adding:

“BAY88 in pre-treated HER2-mut NSCLC.

ORR: 72.1%, mPFS 7.5 months In patients with YVMA ins: ORR 90% and mPFS 9.9 months G3 or higher AEs 43.3% .”

Quoting Biagio Ricciuti‘s post:

“Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study.

ORR: 72.1%, mPFS 7.5 months In patients with YVMA ins: ORR 90% and mPFS 9.9 months G3 or higher AEs 43.3%.”

Source: Xiuning Le/X and Biagio Ricciuti/X

Xiuning Le, MD, serves as the Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, where she oversees clinical research, including strategic planning and the operation of clinical trials within the department. She is also an Associate Professor and a leading translational researcher, specializing in resistance mechanisms, cancer genetics and genomics, biomarkers, and radiomics.

Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.